Armin Schneider
Max Planck Society
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Armin Schneider.
Brain | 2008
Claudia Pitzer; Carola Krüger; Christian Plaas; Friederike Kirsch; Tanjew Dittgen; Ralph Müller; Rico Laage; Stefan Kastner; Stefanie Suess; Robert Spoelgen; Alexandre Henriques; Hannelore Ehrenreich; Wolf-Rüdiger Schäbitz; Alfred Bach; Armin Schneider
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that results in progressive loss of motoneurons, motor weakness and death within 1–5 years after disease onset. Therapeutic options remain limited despite a substantial number of approaches that have been tested clinically. In particular, various neurotrophic factors have been investigated. Failure in these trials has been largely ascribed to problems of insufficient dosing or inability to cross the blood–brain barrier (BBB). We have recently uncovered the neurotrophic properties of the haematopoietic protein granulocyte-colony stimulating factor (G-CSF). The protein is clinically well tolerated and crosses the intact BBB. This study examined the potential role of G-CSF in motoneuron diseases. We investigated the expression of the G-CSF receptor in motoneurons and studied effects of G-CSF in a motoneuron cell line and in the SOD1(G93A) transgenic mouse model. The neurotrophic growth factor was applied both by continuous subcutaneous delivery and CNS-targeted transgenic overexpression. This study shows that given at the stage of the disease where muscle denervation is already evident, G-CSF leads to significant improvement in motor performance, delays the onset of severe motor impairment and prolongs overall survival of SOD1(G93A)tg mice. The G-CSF receptor is expressed by motoneurons and G-CSF protects cultured motoneuronal cells from apoptosis. In ALS mice, G-CSF increased survival of motoneurons and decreased muscular denervation atrophy. We conclude that G-CSF is a novel neurotrophic factor for motoneurons that is an attractive and feasible drug candidate for the treatment of ALS.
Archive | 2010
Armin Schneider; Tanjew Dittgen
Archive | 2002
Armin Schneider; Martin H. Maurer; Wolfgang Kuschinsky; Sylvia Grünewald; Nikolaus Gassler
Archive | 2011
Armin Schneider; Robert Spoelgen; Annette Meyer
Archive | 2011
Armin Schneider; Robert Spoelgen; Tanjew Dittgen; Caludia Dr. Pitzer; Christian Plaas
Archive | 2010
Armin Schneider; Tanjew Dittgen
Archive | 2009
Armin Schneider; Tanjew Dittgen
Archive | 2009
Armin Schneider; Tanjew Dittgen
Archive | 2002
Nikolaus Gassler; Sylvia Grünewald; Wolfgang Kuschinsky; Martin H. Maurer; Armin Schneider
Archive | 2002
Armin Schneider; Martin H. Maurer; Wolfgang Kuschinsky; Sylvia Grünewald; Nikolaus Gassler